Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Paychex, Inc. (PAYX) vs Viatris Inc (VTRS) Price & Performance

Paychex, Inc.Trade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Paychex, Inc. vs Viatris Inc — how do they compare? Paychex, Inc. trades at $114.78 (market cap $43.33B), while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Paychex, Inc. is far larger — about 2.3× Viatris Inc's market cap, and Paychex, Inc. pays the higher dividend (3.91%). Which is the better fit depends on your goals.

PAYXVTRS
Market Cap
$43.33B$19.09B
Sector
IndustrialsHealth
52-Week High
$135.46$17.86
52-Week Low
$85.57$9.49
Enterprise Value
$46.81B$31.21B
Dividend Yield
3.91%2.89%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Paychex, Inc.

Paychex (PAYX) trades at $116.93, down 3.93% over the past day, near the consensus price target of $118.17. The stock shows strong profitability with a 27.03% net income margin and 44.77% ROE, though valuation ratios like a P/E of 24.89 and P/S of 6.73 are elevated. Recent quarters have consistently beaten EPS estimates, and the company is advancing its AI-driven WISE platform to enhance payroll efficiency. Technical indicators are mixed, with a bearish moving average signal but an oversold RSI suggesting potential near-term support.

The outlook for PAYX is cautiously optimistic, supported by steady earnings beats and strategic AI integration, but high valuation and mixed analyst sentiment pose risks. Investment opportunity lies in continued execution on margin expansion and market share gains in HR solutions, while key risks include competitive pressures and economic sensitivity affecting small business clients.

Viatris Inc

Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.

The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Paychex, Inc.

Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.

Read more on PAYX

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS